California Public Employees Retirement System Maintains Stake in Aquinox Pharmaceuticals, Inc. (AQXP)
California Public Employees Retirement System continued to hold its position in Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) during the first quarter, Holdings Channel reports. The fund owned 56,800 shares of the company’s stock at the end of the first quarter. California Public Employees Retirement System’s holdings in Aquinox Pharmaceuticals were worth $948,000 as of its most recent filing with the SEC.
Shares of Aquinox Pharmaceuticals, Inc. (NASDAQ AQXP) traded up 0.53% during midday trading on Friday, reaching $13.17. 28,620 shares of the company’s stock traded hands. Aquinox Pharmaceuticals, Inc. has a 1-year low of $8.76 and a 1-year high of $19.97. The stock’s market capitalization is $308.48 million. The firm’s 50-day moving average price is $14.49 and its 200 day moving average price is $15.46.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, hitting the consensus estimate of ($0.59). On average, equities analysts predict that Aquinox Pharmaceuticals, Inc. will post ($2.15) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “California Public Employees Retirement System Maintains Stake in Aquinox Pharmaceuticals, Inc. (AQXP)” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/13/california-public-employees-retirement-system-maintains-stake-in-aquinox-pharmaceuticals-inc-aqxp.html.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 9th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 8th. BidaskClub upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Cantor Fitzgerald set a $28.00 target price on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 9th. Finally, ValuEngine upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $22.25.
In other Aquinox Pharmaceuticals news, insider David Main sold 15,625 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $13.26, for a total transaction of $207,187.50. Following the completion of the transaction, the insider now owns 77,530 shares in the company, valued at approximately $1,028,047.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.70% of the company’s stock.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Want to see what other hedge funds are holding AQXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP).
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.